Browse SRRD

Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF07985 SRR1
Function

May be involved in a circadian clock input pathway.

> Gene Ontology
 
Biological Process GO:0048511 rhythmic process
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRRD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRRD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.13; FDR: 0.00700 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRRD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0230.931
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2180.908
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1250.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0090.971
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0150.992
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0020.999
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0720.812
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.160.904
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3590.802
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0260.983
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.160.93
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0580.309
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRRD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRRD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRRD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRRD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRRD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRRD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRRD
NameSRR1 domain containing
Aliases HC/HCC; SRR1L; hepatocellular carcinoma complicating hemochromatosis; SRR1 domain-containing protein; SRR1-l ......
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRRD collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.